X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA DISHMAN PHARMA ALEMBIC PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 26.1 25.1 104.0% View Chart
P/BV x 6.0 3.3 177.9% View Chart
Dividend Yield % 0.8 0.7 119.1%  

Financials

 ALEMBIC PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
DISHMAN PHARMA
Mar-16
ALEMBIC PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs792374 211.5%   
Low Rs443129 343.7%   
Sales per share (Unadj.) Rs167.0197.8 84.4%  
Earnings per share (Unadj.) Rs38.221.2 180.0%  
Cash flow per share (Unadj.) Rs42.034.7 120.9%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.60.8 81.5%  
Book value per share (Unadj.) Rs84.9179.9 47.2%  
Shares outstanding (eoy) m188.5280.69 233.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.71.3 290.5%   
Avg P/E ratio x16.211.9 136.3%  
P/CF ratio (eoy) x14.77.2 202.8%  
Price / Book Value ratio x7.31.4 519.8%  
Dividend payout %10.59.4 111.1%   
Avg Mkt Cap Rs m116,38320,306 573.2%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m4,2145,355 78.7%   
Avg. sales/employee Rs ThNM19,252.7-  
Avg. wages/employee Rs ThNM6,459.5-  
Avg. net profit/employee Rs ThNM2,064.1-  
INCOME DATA
Net Sales Rs m31,48715,961 197.3%  
Other income Rs m55265 20.8%   
Total revenues Rs m31,54216,226 194.4%   
Gross profit Rs m10,0604,103 245.2%  
Depreciation Rs m7221,091 66.2%   
Interest Rs m37944 3.9%   
Profit before tax Rs m9,3562,334 400.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-21 -136.4%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,160624 346.4%   
Profit after tax Rs m7,1941,711 420.4%  
Gross profit margin %31.925.7 124.3%  
Effective tax rate %23.126.7 86.4%   
Net profit margin %22.810.7 213.1%  
BALANCE SHEET DATA
Current assets Rs m15,06611,018 136.7%   
Current liabilities Rs m7,6749,517 80.6%   
Net working cap to sales %23.59.4 249.6%  
Current ratio x2.01.2 169.6%  
Inventory Days Days67110 60.6%  
Debtors Days Days4135 116.6%  
Net fixed assets Rs m8,23716,304 50.5%   
Share capital Rs m377161 233.6%   
"Free" reserves Rs m15,41612,907 119.4%   
Net worth Rs m16,00514,516 110.3%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m24,59429,805 82.5%  
Interest coverage x255.23.5 7,353.5%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.30.5 239.1%   
Return on assets %29.48.9 330.0%  
Return on equity %44.911.8 381.3%  
Return on capital %58.717.5 334.7%  
Exports to sales %55.724.8 224.9%   
Imports to sales %10.43.7 279.1%   
Exports (fob) Rs m17,5513,956 443.6%   
Imports (cif) Rs m3,283596 550.6%   
Fx inflow Rs m17,8114,952 359.7%   
Fx outflow Rs m5,318697 763.2%   
Net fx Rs m12,4934,255 293.6%   
CASH FLOW
From Operations Rs m9,3042,786 333.9%  
From Investments Rs m-3,105-1,529 203.1%  
From Financial Activity Rs m-1,959-941 208.2%  
Net Cashflow Rs m4,240316 1,340.1%  

Share Holding

Indian Promoters % 74.1 61.4 120.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 3.7 78.4%  
FIIs % 9.1 12.7 71.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 22.1 62.9%  
Shareholders   49,328 46,261 106.6%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT LTD.  AUROBINDO PHARMA  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Aug 23, 2017 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS